Skip to main content
. 2025 Oct 30;15:175. doi: 10.1186/s13613-025-01578-1

Table 2.

Univariate analysis of factors associated with poor outcome at 6 months among ICU survivors

Variables Died or alive with ECOG 3 or 4 at 6 months
(n = 62)
Alive with ECOG
≤ 2 at 6 months
(n = 140)
p value
Baseline patient characteristics
 Age, years 62 ± 12 63 ± 13 0.614
 Sex, male, n (%) 37 (60%) 90 (64%) 0.640
 Body mass index, kg/m2 24 ± 5.8 25 ± 5.8 0.211
 Body mass index < 18.5 kg/m2, n (%) 10 (16%) 9 (6%) 0.058
 Simplified Acute Physiology score II 43 ± 14 42 ± 14 0.621
 ECOG performance status 3 or 4, n (%) 14 (23%) 15 (11%) 0.045
 Charlson comorbidity score 3.8 ± 2.7 3.2 ± 2.0 0.088
Underlying condition, n (%)
 Type of immunosuppression < 0.001
 Hematological malignancy 28 (45%) 74 (53%)
 Solid cancer 23 (37%) 19 (14%)
 Other a 11 (18%) 47 (34%)
During intensive care unit stay
 Randomization in the noninvasive ventilation arm, n (%) 28 (45%) 67 (48%) 0.840
 ARDS according to the new definition at randomization, n (%) 0.999
 No or mild ARDS 26 (42%) 58 (41%)
 Moderate or severe ARDS 36 (58%) 82 (59%)
 Bronchoalveolar lavage, n (%) 20 (32%) 57 (41%) 0.670
 CT-scan, n (%) 37 (60%) 91 (65%) 0.572
 Change in immunosuppressive drug regimen, n (%) 18 (29%) 36 (26%) 0.750
 Renal replacement therapy, n (%) 7 (11%) 12 (8.6%) 0.727
 Need for norepinephrine within 3 days after randomization, n (%) 8 (13%) 11 (7.9%) 0.365
 Intubation, n (%) 16 (26%) 43 (31%) 0.589
 Duration of mechanical ventilation, days 10 ± 7 12 ± 9 0.433
 Reintubation, n (%) 1 (6%) 3 (7%) 1.000
 Decision to forgo life-sustaining therapies, n (%) 16 (26%) 6 (4.3%) < 0.001
Cause of respiratory failure, n (%)
 Microbiologically documented lung infection 24 (39%) 79 (56%) 0.030
 Specific 11 (18%) 13 (9.3%) 0.140
 Toxic cause 3 (4.8%) 8 (5.7%) 0.999
 Cardiogenic pulmonary edema 2 (3.23%) 9 (6.4%) 0.556
 Miscellaneous 5 (8.1%) 12 (8.6%) 0.999
 No diagnosis 15 (24%) 18 (13%) 0.071
Short-term outcomes
 Length of stay in the ICU, days 7 [5–12] 8 [5–14] 0.122
 Length of stay in the hospital, days 22 [14–36] 19 [13–31] 0.596
 Length of hospital stay after ICU discharge, days 12 [5–22] 10 [6–18] 0.542

Qualitative variables are expressed in number (percentage), quantitative variables are expressed in mean ± standard deviation or median [25th−75th percentile] according to their distribution

ECOG: Eastern Cooperative Oncology Group; ARDS: acute respiratory distress syndrome; CT-scan: computed tomography scan; ICU: intensive care unit

a Acquired immune deficiency syndrome, solid organ transplant or immunosuppressive drugs for connective tissue disease